KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $1.6 billion.

  • Biomarin Pharmaceutical's Total Liabilities rose 837.1% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 837.1%. This contributed to the annual value of $1.3 billion for FY2024, which is 2958.14% down from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Total Liabilities stood at $1.6 billion, which was up 837.1% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Total Liabilities ranged from a high of $1.9 billion in Q4 2023 and a low of $1.3 billion during Q4 2024
  • In the last 5 years, Biomarin Pharmaceutical's Total Liabilities had a median value of $1.7 billion in 2022 and averaged $1.7 billion.
  • In the last 5 years, Biomarin Pharmaceutical's Total Liabilities soared by 1080.09% in 2021 and then crashed by 2958.14% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Total Liabilities (Quarter) stood at $1.7 billion in 2021, then grew by 1.89% to $1.8 billion in 2022, then increased by 6.67% to $1.9 billion in 2023, then decreased by 29.58% to $1.3 billion in 2024, then increased by 17.07% to $1.6 billion in 2025.
  • Its Total Liabilities was $1.6 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.4 billion in Q1 2025.